AGENT™
Drug-Coated Balloon
Data from the first coronary drug-coated balloon (DCB) study in U.S. met the 1-year primary endpoint and demonstrated low adverse event rates. The AGENT IDE Clinical Trial showed that AGENT DCB is superior to conventional balloon angioplasty in reducing target lesion failure for the treatment of coronary in-stent restenosis (ISR).
AGENT IDE Clinical Trial
Primary Endpoint²
Additional Endpoints²
At 1-year, AGENT DCB also demonstrated statistically lower event rates:
- 50% risk reduction in TLR (13.0% vs. 24.7%, P=0.0005)
- 49% risk reduction in TV-MI (5.8% vs. 11.1%, P=0.023)
- Zero definite/probable ST (0.0% vs. 3.2%, P=0.0004)